FDA grants Endo Pharmaceuticals approval for new Opana strengths

CHADDS FORD, Pa. Endo Pharmaceuticals Holdings has received approval from the Food and Drug Administration for three new strengths of its pain drug Opana ER, according to the Associated Press.

The new dosages are: 7.5 mg, 15 mg, and 30 mg. The doses will be available on April 1.

Cowen analyst Ian Sanderson has said that Opana sales in 2008 in the U.S. should be $140 million and by 2012, it could hit $420 million based on hoped that the drug captures a 6 percent share of the opioid market.

Login or Register to post a comment.